Oraqix (Lidocaine, Prilocaine)

Oraqix is a topical anesthetic used in dentistry to provide localized numbness of oral mucosal tissues.

• Dental procedures: Reduces pain and discomfort during minor surgical interventions such as extractions and biopsies.
• Periodontal therapy: Facilitates scaling, root planing and other non‑surgical periodontal treatments.
• Diagnostic examinations: Allows comfortable probing and assessment of oral lesions.
• Pediatric dentistry: Provides a child‑friendly anesthetic option for simple restorative work.
• Oral mucosal lesions: Helps alleviate pain from traumatic or ulcerative lesions.
• Pre‑operative preparation: Used to anesthetize the site before more invasive oral surgery.

• Lidocaine and Prilocaine act as reversible sodium‑channel blockers on peripheral nerve membranes. By inhibiting the influx of sodium ions, they prevent the generation and propagation of action potentials, resulting in a temporary loss of sensory perception in the applied area. The combined formulation provides rapid onset of surface anesthesia with a duration suitable for most dental procedures.

Oraqix may cause local or systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

• Transient burning or stinging sensation at the application site.
• Mild erythema or redness of the oral mucosa.
• Temporary alteration of taste perception.
• Minor swelling or edema of the gingival tissue.
• Light‑headed dizziness if absorbed in larger amounts.

Serious or Rare Side Effects

• Allergic reactions such as urticaria, angio‑edema or anaphylaxis.
• Methemoglobinemia, particularly with excessive exposure to prilocaine.
• Persistent numbness beyond the expected duration.
• Cardiovascular disturbances including hypotension or arrhythmia.
• Central nervous system toxicity presenting as seizures or altered consciousness.

When using Oraqix, clinicians should assess patient history and follow recommended handling practices.

• Allergy assessment: Verify no known hypersensitivity to lidocaine, prilocaine or amide‑type anesthetics.
• Dose limitation: Avoid exceeding the maximum recommended surface area to reduce systemic absorption.
• Medical conditions: Use caution in patients with cardiac, hepatic or renal impairment.
• Drug interactions: Review concurrent medications that may potentiate local anesthetic toxicity.
• Pediatric use: Adjust application area and monitor closely in children.
• Store at ambient temperature: Keep below 25°C, protect from moisture and direct sunlight.

Oraqix can interact with systemic medications that affect cardiac conduction or increase the risk of local‑anesthetic toxicity.

Major Interactions (Avoid)

• Class I anti‑arrhythmic agents (e.g., quinidine, procainamide) – may exacerbate cardiac conduction delays.
• Monoamine oxidase inhibitors (MAOIs) – increase risk of systemic toxicity when large amounts are absorbed.

Moderate Interactions (Monitor Closely)

• Beta‑blockers and calcium‑channel blockers – may potentiate hypotensive effects.
• CNS depressants (e.g., benzodiazepines, opioids) – enhance central nervous system depression if systemic absorption occurs.
• Certain antibiotics such as erythromycin – can alter plasma protein binding of local anesthetics.
• Anticoagulants (e.g., warfarin) – may increase bleeding risk at the application site.
• Herbal supplements containing ephedra – may raise blood pressure and heart rate, influencing anesthetic safety.